GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 454
- Registration Number
- NCT00158795
- Locations
- 🇨🇳
GSK Investigational Site, Nanning, Guangxi, China
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 224
- Registration Number
- NCT00158873
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00158834
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 308
- Registration Number
- NCT00158756
- Locations
- 🇷🇺
GSK Investigational Site, Tomsk, Russian Federation
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00148902
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00148928
- Locations
- 🇫🇷
GSK Investigational Site, Villejuif Cedex, France
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4209
- Registration Number
- NCT00148941
- Locations
- 🇺🇸
GSK Investigational Site, Mechanicsville, Virginia, United States
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120794
- Registration Number
- NCT00146835
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT00146744
- Locations
- 🇨🇭
GSK Investigational Site, Lausanne, Switzerland
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00144872
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States